Day 1 | Day 2 | Download Brochure
TUESDAY, JUNE 5
7:15 am Registration & Morning Coffee
8:30 Chairperson’s Opening Remarks
Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories
8:40 Cellular QT Screens - Probing Adult Cardiac Myocytes
Lars Kaestner, Ph.D., Principal Investigator, Institute for Molecular Cell Biology, Saarland University
9:10 Evaluation of Cellular Impedance Measures of Cardiomyocyte Cultures for Drug Screening Applications
Matthew Peters, Ph.D., Principal Scientist, Safety Assessment, Astrazeneca
9:40 The Tell Tale Heart: Integration of Whole Heart Energetics, Proteomics, and Function to Assess Cardiac Toxicity in the Isolated Heart
Brian Roche, Ph.D., Cardiovascular Safety Pharmacologist, Safety Pharmacology, Battelle Memorial Institute
10:10 Coffee Break
10:40 Cardiac Contractility: Challenges in De-Risking
Jonathan Heyen, Ph.D., Principal Scientist, Global Safety Pharmacology, Pfizer Global Research & Development
11:10 Translating Cardiotoxicity: Can Stem Cells “Swim” Like Humans?
Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories;
11:40 Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Understand Mechanisms of Cardiotoxicity
Dinesh Puppala, Ph.D., Senior Scientist, Compound Safety Prediction Group, Pfizer, Inc.
Sponsored by
12:10 pm Sponsored Presentation
Speaker to be Announced
12:25 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own
1:10 Session Break
1:30 Chairperson’s Remarks
Peter Hoffmann, M.D., Ph.D., Executive Director, Preclinical Safety and Translational Cardiovascular Advisory Team, Novartis Pharmaceuticals Corporation
1:40 Cardiac Sodium Channel Inhibition: A Risk Marker During Early Drug Development
Peter Hoffmann, M.D., Ph.D., Executive Director, Pre-Clinical Safety and Translational Cardiovascular Advisory Team, Novartis Pharmaceuticals Corporation
2:10 What is New About hERG Channel Inhibition? Atypical hERG Inhibition and Mitigation Strategies
Gul Erdemli, M.D., Ph.D., DABT, Head, Ion Channel Group, Novartis Institutes for BioMedical Research, Inc.
2:40 Regional Genomic Regulation of Cardiac Ion Channels by Estrogen and its Implications to Sex Differences in Arrhythmia Risk
Guy Salama, Ph.D., Professor, Department of Medicine, University of Pittsburgh, School of Medicine
Sponsored by
3:10 Translational Cardiovascular Safety:
Optimizing the Integration of Pre-Clinical and Clinical Safety Data
Sarah S. Bacus, Ph.D., CSO & Senior Vice President, Innovation, Quintiles Pacific, Inc.
3:40 Refreshment Break in the Exhibit Hall with Poster Viewing
4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.
5:40 Welcome Reception in the Exhibit Hall with Poster Viewing
6:45 End of Day
Day 1 | Day 2 | Download Brochure